Advertisement
Prime Medicine, Inc. (PRME)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 2.9700 |
| Open | 3.0400 |
| Bid | 3.1700 x 400 |
| Ask | 3.2300 x 300 |
| Day's Range | 2.9450 - 3.2900 |
| 52 Week Range | 2.8500 - 9.8600 |
| Volume | |
| Avg. Volume | 1,557,500 |
| Market Cap | 419.715M |
| Beta (5Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0600 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.64 |
Simply Wall St.Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
GlobeNewswirePrime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments -- -- On track to report initial data from Phase 1/2 clinical trial of P
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.